What Is ANI Pharmaceuticals, Inc. (ANIP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ANI Pharmaceuticals, Inc. presents a highly debated valuation profile at its current price of $81.08. The composite intrinsic value is estimated at $80.80 (-0.3% average upside), masking a wide model spread between the 4 bullish models and 6 bearish models. Model dispersion is worth noting: First Chicago targets $167.95 (+107.1%), versus Dynamic NAV at $1.63 (-98.0%). This +205.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ANIP?
12 of 13 models are currently active for ANIP. Of these, 4 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates ANIP's intrinsic value at $33.15, implying -59.1% downside from the current price. See which stocks rank higher →
How Does ANIP Rank in Drug Manufacturers - Specialty & Generic?
Among 13 Drug Manufacturers - Specialty & Generic stocks, ANIP ranks #4 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.
ANI Pharmaceuticals, Inc.'s positioning within the Drug Manufacturers - Specialty & Generic segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.
Is ANIP a Value Trap?
CirclFi's Value Trap algorithm assigns ANIP a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for ANI Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, ANI Pharmaceuticals, Inc. earns a quality score of 7.5/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +205.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ANIP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ANIP's 12 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad